Bone mineral density in children with beta-thalassemia major in Diyarbakir

被引：32

作者：

Pirinccioglu, Ayfer Gozu ^{[1
]}

Akpolat, Veysi ^{[2
]}

Koksal, Orhan ^{[1
]}

Haspolat, Kenan ^{[1
]}

Soker, Murat ^{[1
]}

机构：

[1] Dicle Univ, Fac Med, Dept Pediat, TR-21280 Diyarbakir, Turkey

[2] Dicle Univ, Fac Med, Dept Med Phys, TR-21280 Diyarbakir, Turkey

来源：

BONE | 2011年 / 49卷 / 04期

关键词：

Bone mineral density; Children; Osteoporosis; Osteopenia; Beta-thalassemia; PREPUBERTAL CHILDREN; BIOCHEMICAL MARKERS; OSTEOPOROSIS; TURNOVER; ADOLESCENTS; DISEASE; MASS; 1,25-DIHYDROXYVITAMIN-D; METABOLISM; INSIGHTS;

D O I：

10.1016/j.bone.2011.07.014

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bone mineral status has extensively been investigated in adult thalassemics but less in thalassemic children. This study involves measurements of the bone mineral density (BMD), various demographic and biochemical parameters in 47 thalassemic children and 50 healthy controls with comparable age, sex, socioeconomic and regional distribution. Patients have significantly higher aspartate aminotransferase, alanine aminotransferase, phosphorous, osteocalcin, serum carboxy terminal teleopeptide fragment of type I collagen, intact parathyroid hormone (iPTH) and ferritin levels while they have significantly lower 25-hydroxy vitamin D (25OH-D), alkaline phosphatase and z-scores both at lumbar and femur compared to controls. Patients with high iPTH (30%) had significantly lower z-scores and 25OH-D while larger osteocalcin. We conclude that a significantly lower BMD in beta-thalassemic children compared with their healthy counterparts is a complex process and may partially attributed to their slower physical development, caused by iron overload and chelation therapy which may influence the liver as well as the endocrine tissues. (C) 2011 Elsevier Inc. All rights reserved.

引用

页码：819 / 823

页数：5

共 37 条

[11]

HEANEY RP, 1993, ANNU REV NUTR, V13, P287, DOI 10.1146/annurev.nu.13.070193.001443

[12]

Jensen CE, 1998, J PEDIATR ENDOCR MET, V11, P975

[13]

Jensen CE, 1997, EUR J HAEMATOL, V59, P76

[14]

Jensen CE, 1998, BRIT J HAEMATOL, V103, P911

[15]

JOHANSON NA, 1990, ORTHOP CLIN N AM, V21, P191

[16] Osteoporosis and β-thalassemia major:: Role of the IGF-I/IGFBP-III axis [J].

Lasco, A ;

Morabito, N ;

Gaudio, A ;

Crisafulli, A ;

Meo, A ;

Denuzzo, G ;

Frisina, N .

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2002, 25 (04) :338-344

[17] Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with β-thalassaemia disease [J].

Mahachoklertwattana, P ;

Chuansumrit, A ;

Sirisriro, R ;

Choubtum, L ;

Sriphrapradang, A ;

Rajatanavin, R .

CLINICAL ENDOCRINOLOGY, 2003, 58 (03) :273-279

[18]

Mahachoklertwattana P, 2002, J PEDIATR ENDOCR MET, V15, P1531

[19] Bone mineral density of patients with thalassemia major: Four-year follow-up [J].

Molyvda-Athanasopoulou, E ;

Sioundas, A ;

Karatzas, N ;

Aggellaki, M ;

Pazaitou, K ;

Vainas, I .

CALCIFIED TISSUE INTERNATIONAL, 1999, 64 (06) :481-484

[20] Bisphosphonates in the treatment of thalassemia-induced osteoporosis [J].

Morabito, N ;

Lasco, A ;

Gaudio, A ;

Crisafulli, A ;

Di Pietro, C ;

Meo, A ;

Frisina, N .

OSTEOPOROSIS INTERNATIONAL, 2002, 13 (08) :644-649

← 1 2 3 4 →